Table 3 Risk estimation between TNFR2 genotypes and HBV-related diseases in males.
SNP | CHB vs Controls | LC vs Controls | HCC vs Controls | |||
|---|---|---|---|---|---|---|
R(95%CI)* | P* | R(95%CI)* | P* | R(95%CI)* | P* | |
rs1061622 | ||||||
T | Reference | Reference | Reference | |||
G | 0.718 (0.362–1.421) | 0.341 | 0.778 (0.392–1.545) | 0.474 | 1.043 (0.684–1.591) | 0.845 |
TT | Reference | Reference | Reference | |||
TG | 0.698 (0.327–1.488) | 0.351 | 0.656 (0.301–1.430) | 0.289 | 1.108 (0.687–1.787) | 0.647 |
GG | 0.374 (0.007–20.029) | 0.629 | 1.878 (0.154–22.876) | 0.621 | 0.625 (0.085–4.585) | 0.644 |
Dominant model | ||||||
TT | Reference | Reference | Reference | |||
TG + GG | 0.688 (0.342–1.461) | 0.331 | 0.695 (0.325–1.483) | 0.246 | 1.082 (0.677–1.731) | 0.742 |
Recessive model | ||||||
TT+TG | Reference | Reference | Reference | |||
GG | 0.431 (0.008–23.782) | 0.681 | 2.129 (0.352–1.483) | 0.346 | 0.610 (0.084–4.452) | 0.626 |
rs1061624 | ||||||
G | Reference | Reference | Reference | |||
A | 1.668 (1.056–2.634) | 0.028# | 1.492 (0.972–2.288) | 0.067 | 1.268 (0.943–1.705) | 0.116 |
GG | Reference | Reference | Reference | |||
GA | 1.649 (0.767–3.547) | 0.200 | 1.747 (0.824–3.703) | 0.146 | 1.548 (0.966–2.479) | 0.069 |
AA | 4.280 (1.405–13.041) | 0.011# | 3.361 (1.114–10.146) | 0.031# | 1.882 (0.831–4.267) | 0.130 |
Dominant model | ||||||
GG | Reference | Reference | Reference | |||
GA + AA | 1.953 (0.928–4.108) | 0.078 | 0.519 (0.249–1.084) | 0.081 | 1.584 (0.997–2.517) | 0.052 |
Recessive model | ||||||
GG+GA | Reference | Reference | Reference | |||
AA | 3.032 (1.146–8.021) | 0.025# | 2.258 (0.867–5.878) | 0.095 | 1.381 (0.653–2.920) | 0.398 |
